BICARA THERAPEUTICS INC (BCAX) Stock Price, Quote, News and Overview
NASDAQ:BCAX - Nasdaq - US0554771032 - Currency: USD
BCAX Quote, Performance and Key Statistics
16.55
+0.8 (+5.08%)
The current stock price of BCAX is 16.55 USD. In the past month the price increased by 31.35%.
BCAX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About BCAX
Company Profile
Bicara Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2024-09-13. Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
Company Info
BICARA THERAPEUTICS INC
116 Huntington Avenue, Suite 703
Boston MASSACHUSETTS US
Employees: 32
Company Website: https://www.bicara.com/
Phone: 16174684219
BICARA THERAPEUTICS INC / BCAX FAQ
What is the stock price of BICARA THERAPEUTICS INC today?
The current stock price of BCAX is 16.55 USD. The price increased by 5.08% in the last trading session.
What is the ticker symbol for BICARA THERAPEUTICS INC stock?
The exchange symbol of BICARA THERAPEUTICS INC is BCAX and it is listed on the Nasdaq exchange.
On which exchange is BCAX stock listed?
BCAX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BICARA THERAPEUTICS INC stock?
12 analysts have analysed BCAX and the average price target is 40.55 USD. This implies a price increase of 144.98% is expected in the next year compared to the current price of 16.55. Check the BICARA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BICARA THERAPEUTICS INC worth?
BICARA THERAPEUTICS INC (BCAX) has a market capitalization of 900.65M USD. This makes BCAX a Small Cap stock.
How many employees does BICARA THERAPEUTICS INC have?
BICARA THERAPEUTICS INC (BCAX) currently has 32 employees.
What are the support and resistance levels for BICARA THERAPEUTICS INC (BCAX) stock?
BICARA THERAPEUTICS INC (BCAX) has a support level at 12.56. Check the full technical report for a detailed analysis of BCAX support and resistance levels.
Should I buy BICARA THERAPEUTICS INC (BCAX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BCAX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BCAX, evaluating the profitability, health, valuation and growth aspects
- BICARA THERAPEUTICS INC (BCAX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BICARA THERAPEUTICS INC (BCAX) Sales and EPS estimates to see what analysts future expectations are.
- BICARA THERAPEUTICS INC (BCAX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BICARA THERAPEUTICS INC (BCAX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BICARA THERAPEUTICS INC (BCAX) Stock Chart to make your own analysis
- BICARA THERAPEUTICS INC (BCAX) Latest news and press-releases to stay up to date.
Does BICARA THERAPEUTICS INC (BCAX) stock pay dividends?
BCAX does not pay a dividend.
What is the Price/Earnings (PE) ratio of BICARA THERAPEUTICS INC (BCAX)?
BICARA THERAPEUTICS INC (BCAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1).
What is the Short Interest ratio of BICARA THERAPEUTICS INC (BCAX) stock?
The outstanding short interest for BICARA THERAPEUTICS INC (BCAX) is 8.73% of its float. Check the ownership tab for more information on the BCAX short interest.
BCAX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BCAX.
BCAX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BCAX. While BCAX has a great health rating, there are worries on its profitability.
BCAX Financial Highlights
Over the last trailing twelve months BCAX reported a non-GAAP Earnings per Share(EPS) of -1. The EPS decreased by -37.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.92% | ||
| ROE | -10.2% | ||
| Debt/Equity | 0 |
BCAX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to BCAX. The Buy consensus is the average rating of analysts ratings from 12 analysts.